Trial Profile
Evaluation of the Safety and Performance of the Zilver® PTX™ Drug-Eluting Stent for Treating De Novo or Restenotic Lesions of the Above-the-knee Femoropopliteal Artery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral arterial occlusive disorders; Restenosis
- Focus Therapeutic Use
- Sponsors Cook Medical
- 05 Nov 2010 New trial record.